TY - JOUR
T1 - Occupational risk of SARS-CoV-2 infection and reinfection during the second pandemic surge
T2 - a cohort study
AU - SEROCoV-WORK+ study group
AU - Leidi, Antonio
AU - Berner, Amandine
AU - Dumont, Roxane
AU - Dubos, Richard
AU - Koegler, Flora
AU - Piumatti, Giovanni
AU - Vuilleumier, Nicolas
AU - Kaiser, Laurent
AU - Balavoine, Jean François
AU - Trono, Didier
AU - Pittet, Didier
AU - Chappuis, François
AU - Kherad, Omar
AU - Courvoisier, Delphine Sophie
AU - Azman, Andrew S.
AU - Zaballa, Maria Eugenia
AU - Guessous, Idris
AU - Stringhini, Silvia
N1 - Publisher Copyright:
© 2022 BMJ Publishing Group. All rights reserved.
PY - 2022/2
Y1 - 2022/2
N2 - Objectives This cohort study including essential workers, assessed the risk and incidence of SARS-CoV-2 infection during the second surge of COVID-19 according to baseline serostatus and occupational sector. Methods Essential workers were selected from a seroprevalence survey cohort in Geneva, Switzerland and were linked to a state centralised registry compiling SARS-CoV-2 infections. Primary outcome was the incidence of virologically confirmed infections from serological assessment (between May and September 2020) to 25 January 2021, according to baseline antibody status and stratified by three predefined occupational groups (occupations requiring sustained physical proximity, involving brief regular contact or others). Results 10 457 essential workers were included (occupations requiring sustained physical proximity accounted for 3057 individuals, those involving regular brief contact, 3645 and 3755 workers were classified under’Other essential occupations’). After a follow-up period of over 27 weeks, 5 (0.6%) seropositive and 830 (8.5%) seronegative individuals had a positive SARS-CoV-2 test, with an incidence rate of 0.2 (95% CI 0.1 to 0.6) and 3.2 (95% CI 2.9 to 3.4) cases per person-week, respectively. Incidences were similar across occupational groups. Seropositive essential workers had a 93% reduction in the hazard (HR of 0.07, 95% CI 0.03 to 0.17) of having a positive test during the follow-up with no significant between-occupational group difference. Conclusions A 10-fold reduction in the hazard of being virologically tested positive was observed among anti-SARS-CoV-2 seropositive essential workers regardless of their sector of occupation, confirming the seroprotective effect of a previous SARS-CoV2 exposure at least 6 months after infection.
AB - Objectives This cohort study including essential workers, assessed the risk and incidence of SARS-CoV-2 infection during the second surge of COVID-19 according to baseline serostatus and occupational sector. Methods Essential workers were selected from a seroprevalence survey cohort in Geneva, Switzerland and were linked to a state centralised registry compiling SARS-CoV-2 infections. Primary outcome was the incidence of virologically confirmed infections from serological assessment (between May and September 2020) to 25 January 2021, according to baseline antibody status and stratified by three predefined occupational groups (occupations requiring sustained physical proximity, involving brief regular contact or others). Results 10 457 essential workers were included (occupations requiring sustained physical proximity accounted for 3057 individuals, those involving regular brief contact, 3645 and 3755 workers were classified under’Other essential occupations’). After a follow-up period of over 27 weeks, 5 (0.6%) seropositive and 830 (8.5%) seronegative individuals had a positive SARS-CoV-2 test, with an incidence rate of 0.2 (95% CI 0.1 to 0.6) and 3.2 (95% CI 2.9 to 3.4) cases per person-week, respectively. Incidences were similar across occupational groups. Seropositive essential workers had a 93% reduction in the hazard (HR of 0.07, 95% CI 0.03 to 0.17) of having a positive test during the follow-up with no significant between-occupational group difference. Conclusions A 10-fold reduction in the hazard of being virologically tested positive was observed among anti-SARS-CoV-2 seropositive essential workers regardless of their sector of occupation, confirming the seroprotective effect of a previous SARS-CoV2 exposure at least 6 months after infection.
UR - http://www.scopus.com/inward/record.url?scp=85123651780&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123651780&partnerID=8YFLogxK
U2 - 10.1136/oemed-2021-107924
DO - 10.1136/oemed-2021-107924
M3 - Article
C2 - 34880045
AN - SCOPUS:85123651780
SN - 1351-0711
VL - 79
SP - 116
EP - 119
JO - Occupational and Environmental Medicine
JF - Occupational and Environmental Medicine
IS - 2
ER -